Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 136

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1B
Chunk 136
---
 when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.

 66

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 

This item is not required for smaller reporting companies.

 67

Item 8. Financial Statements and Supplementary Data. 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

    Page

    Report of Independent Registered Public Accounting Firm
    69

    Consolidated Balance Sheet as of December 31, 2024 and 2023
    70

    Consolidated Statement of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023
    71

    Consolidated Statement of Stockholders’ Deficit for the Years Ended December 31, 2024 and 2023
    72

    Consolidated Statement of Cash Flows for the Years Ended December 31, 2024 and 2023
    73

    Notes to Consolidated Financial Statements for the Years Ended December 31, 2024 and 2023
    74

 68

Report of Independent Registered Public Accounting Firm 

To the Stockholders and Board of Directors 

MiNK Therapeutics, Inc.: 

Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of MiNK Therapeutics, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.